Products
INTERCEPT™ Blood System for Plasma
The INTERCEPT™ Blood System for Plasma is used by blood centres globally to help protect patients, improve availability, safeguard clinical outcomes and provide operational benefits
Protects Patients
Robust, Broad-Spectrum Pathogen Inactivation
The INTERCEPT™ Blood System for Plasma is used to inactivate a broad spectrum of viruses, bacteria, and parasites, as well as contaminating donor leucocytes in plasma components; reducing the risk of transfusion transmitted infections (TTIs), and the risk of adverse effects due to transfusion of contaminating donor leukocytes.1
Gram-negative, Gram-positive, spirochaetes
- Klebsiella pneumoniae
- Yersinia enterocolitica
- Anaplasma phagocytophilum (HGE agent)
- Enterobacter cloacae
- Pseudomonas aeruginosa
- Gram-Positive Bacteria
- Staphylococcus epidermidis
- Staphylococcus aureus
- Staphylococcus aureus (MRSA)
- Staphylococcus aureus (MSSA)
- Spirochete Bacteria
- Treponema pallidum (syphilis)a
- Borrelia burgdorferi (Lyme disease)
- HIV-1 IIIB, cell-associated
- Hepatitis B virus (HBV)
- Hepatitis C virus (HCV)
- Duck hepatitis B virus (DHBV, model virus for HBV)
- Bovine viral diarrhea virus (BVDV, model virus for HCV)
- Human T-cell lymphotropic virus (HTLV-I & HTLV-II)
- West Nile virus (WNV)
- Chikunguyna virus (CHIKV)
- Dengue virus (DENV)
- Avian influenza virus A (FLUAV)
- SARS-CoV-2
- Zika virus (ZIKV)
- Bluetongue virus (model for non-enveloped virus)
- Human adenovirus 5 (Ad5)
- Parvovirus B19
- Babesia microti (babesiosis)
- Plasmodium falciparum (malaria)
- Trypanosoma cruzi (Chagas’ disease)
- Human T-Cells†‡
Improve availability
A Proactive Approach to Pandemic Preparedness
The availability of safe blood products is critical to achieve optimal patient outcomes. However, blood is becoming an increasingly scarce resource and blood supplies continue to be threatened by a myriad of challenges. The INTERCEPT™ Blood System has demonstrated to help maintain continuity of patient care by helping to ensure plasma transfusions remain safe and accessible to patients during outbreaks or epidemics.2,3,4
Safeguard Clinical Outcomes
Proven in Routine Use
By reducing the risks of TTIs and certain undesirable adverse events, the INTERCEPT™ Blood System contributes to timely and safe blood transfusions while providing therapeutically effective products. INTERCEPT™ Plasma may be prescribed and transfused in accordance with standard transfusion methods.
Provide Operational Benefits
Realise significant operational efficiencies at many steps of the transfusion chain
The INTERCEPT™ Blood System for plasma is flexible and adaptable. It allows a range of INTERCEPT™ Pathogen Inactivated Plasma Products to be manufactured from both apheresis and whole blood derived plasma. The process also allows more plasma to be available to the plasma fractionation industry to produce plasma derived medicinal products (PDMPs).
Operational Benefits of pooling
Pooling 5 whole blood plasma units can yield 6x 200mL plasma units
In comparison to single-unit PI processing, the combination of the INTERCEPT™ Plasma Processing Set and the Plasma Pooling Set offers significant operational benefits. In many cases, 5 whole blood plasma units are an ideal pool size to produce 2 pools of approximately 650mL using the Plasma Pooling Set. Treating these requires just 2 INTERCEPT™ Plasma Processing Sets and yields 6x 200mL plasma units. In contrast, 6 separate sets and treatments are needed to produce 6 PI plasma units from single-unit processes. This process enables an additional plasma unit to become available for use in fractionation, while ensuring the maintenance of fresh frozen plasma (FFP) supply to patients.
The INTERCEPT™ Blood System for Plasma
The INTERCEPT™ Blood System for Plasma consists of an INTERCEPT™ Processing Set for Plasma, which uses amotosalen (a photoactive compound), and the INTERCEPT™ Illuminator, a medical device providing an ultraviolet A (UVA) light source. Together they are used in the ex vivo preparation and storage of pathogen inactivated plasma intended for transfusion.
The INTERCEPT™ Blood System process is formed of 3 simple steps:
Introducing our next-generation LED-based illumination device
The INTERCEPT™ Blood System for Plasma now includes the new INTERCEPT™ Illuminator INT200. Designed to simplify operations, from start to finish, of the pathogen inactivation process.5
The current INTERCEPT™ Illuminator (INT100) was designed to deliver a controlled amount of ultraviolet A (UVA) light emitted by fluorescent bulbs. In recent years, the global lighting industry has experienced a shift from fluorescent bulbs to LED technologies. LED-based technology is utilised in the new replacement for the INT100, known as the INT200 illuminator.
INTERCEPT™ Plasma Processing Set
An INTERCEPT™ Processing Set is available to meet your plasma production needs. The INTERCEPT™ Processing Set for plasma has been designed to treat single units of apheresis plasma or pools of 2 to 3 units of apheresis or whole-blood derived plasma.
Implementing INTERCEPT™
Our experienced deployment team is here to support in every step
The Cerus Deployment Team has been helping blood centres to successfully implement pathogen inactivation for over 10 years. The team is experienced in single centre, multicentre regional and country-wide implementations, and understands how to integrate the INTERCEPT™ Blood System into existing blood banking processes, managing implementation strategies which vary widely in complexity.
References:
- The INTERCEPT Blood System for Plasma Technical Data Sheet, Cerus Corporation.
- Rasongles P et al., 2009. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion. Transfusion 49: 1083-1091
- Marano G et al., 2017. Ten years since the last Chikungunya virus outbreak in Italy: history repeats itself. Blood Transfus 15: 489-590
- Domanovic D et al., 2019. Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting. Blood Transfus 17: 433-448
- Cerus data on-file: INTERCEPT LED Illuminator Summative Human Factors Validation Study Report (DES-HF 00557-02); INTERCEPT LED Illuminator Late Formative Study Report (DES-HF 00643-02)
There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19, and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT™ process. For a full list of warnings, precautions for use and pathogens inactivated, please refer to the Technical Data Sheet and Instructions for Use found in the resource section of this website.